In a statement to investors Wednesday, Moderna said it expects to be able to report the data for its vaccine trials in children ages 2-5 in March. The statement added that if the findings are positive, the company will proceed with regulatory filings for the vaccine.
The CDC has only approved Moderna’s COVID-19 vaccine for adults ages 18 and over in the United States.
Moderna’s vaccine is authorized in Europe, the U.K., Australia and Canada for adolescents as young as 12, Reuters reported. Moderna has submitted applications in Europe, the U.K., Australia, and Canada for the vaccine in children as young as 6.
More coronavirus pandemic coverage:
©2022 Cox Media Group